The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial.
hydroquinone
melasma
methimazole
Journal
Journal of cosmetic dermatology
ISSN: 1473-2165
Titre abrégé: J Cosmet Dermatol
Pays: England
ID NLM: 101130964
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
07
12
2018
revised:
21
03
2019
accepted:
17
04
2019
pubmed:
19
5
2019
medline:
20
11
2020
entrez:
19
5
2019
Statut:
ppublish
Résumé
The management of melasma is still challenging, and new treatment modalities with favorable side effect profile are required. Methimazole, a peroxidase inhibitor, seems to have a beneficial effect in the management of melasma but there is a paucity of studies for evaluation of its efficacy. This double-blinded trial was aimed to evaluate the efficacy and safety of methimazole vs hydroquinone 4% which is the gold standard treatment in the management of melasma. Fifty patients with melasma were enrolled and randomly divided into two groups to receive 4% hydroquinone or 5% methimazole once daily for 8 weeks. Forty patients completed the study. The clinical response was assessed at 4th, 8th, and 12th weeks after treatment by MASI score, patient satisfaction, and physician scores. Both groups showed a reduction in the MASI score at the 8th week which was more significant in hydroquinone group but higher relapse rate was also observed in this group after discontinuing the drug. The side effects were similar between groups. Also, patient and physician satisfaction scores were also more in favor of hydroquinone 4%. Methimazole could be an alternative treatment of melasma alone or in combination with other depigmenting drugs. Although not as effective as hydroquinone, the noncytotoxic and nonmutagenic aspects of methimazole may make it a promising alternative for the treatment of melasma.
Sections du résumé
BACKGROUND
BACKGROUND
The management of melasma is still challenging, and new treatment modalities with favorable side effect profile are required. Methimazole, a peroxidase inhibitor, seems to have a beneficial effect in the management of melasma but there is a paucity of studies for evaluation of its efficacy. This double-blinded trial was aimed to evaluate the efficacy and safety of methimazole vs hydroquinone 4% which is the gold standard treatment in the management of melasma.
METHODS
METHODS
Fifty patients with melasma were enrolled and randomly divided into two groups to receive 4% hydroquinone or 5% methimazole once daily for 8 weeks. Forty patients completed the study. The clinical response was assessed at 4th, 8th, and 12th weeks after treatment by MASI score, patient satisfaction, and physician scores.
RESULTS
RESULTS
Both groups showed a reduction in the MASI score at the 8th week which was more significant in hydroquinone group but higher relapse rate was also observed in this group after discontinuing the drug. The side effects were similar between groups. Also, patient and physician satisfaction scores were also more in favor of hydroquinone 4%.
CONCLUSION
CONCLUSIONS
Methimazole could be an alternative treatment of melasma alone or in combination with other depigmenting drugs. Although not as effective as hydroquinone, the noncytotoxic and nonmutagenic aspects of methimazole may make it a promising alternative for the treatment of melasma.
Substances chimiques
Hydroquinones
0
Methimazole
554Z48XN5E
hydroquinone
XV74C1N1AE
Types de publication
Equivalence Trial
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-172Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56(4):380.
Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65(4):699-714.
Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27(2):96-101.
Pawaskar MD, Parikh P, Markowski T, Mcmichael AJ, Feldman SR, Balkrishnan R. Melasma and its impact on health-related quality of life in Hispanic women. J Dermatolog Treat. 2007;18(1):5-9.
Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. Br J Dermatol. 2007;157(5):874-887.
Sardana K, Ghunawat S. Rationale of using hypopigmenting drugs and their clinical application in melasma. Expert Rev Clin Pharmacol. 2015;8(1):123-134.
Okun M, Donnellan B, Pearson S, Edelstein L. Melanin: a normal component of human eosinophils. Lab Invest. 1974;30(6):681.
Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutical approaches in melasma. Dermatol Clin. 2007;25(3):337-342, viii.
Kasraee B. Peroxidase-mediated mechanisms are involved in the melanocytotoxic and melanogenesis-inhibiting effects of chemical agents. Dermatology. 2002;205(4):329-339.
Shiroozu A, Taurog A, Engler H, et al. Mechanism of action of thioureylene antithyroid drugs in the rat: possible inactivation of thyroid peroxidase by propylthiouracil. Endocrinology. 1983;113(1):362-370.
Kasraee B, Handjani F, Parhizgar A, et al. Topical methimazole as a new treatment for postinflammatory hyperpigmentation: report of the first case. Dermatology. 2005;211(4):360-362.
Akatsuka K, Hashimoto T, Takeuchi K, Ohhira M. Mutagenicity test of antithyroid agent, methimazole: dominant lethal mutation test on male mice. J Toxicol Sci. 1979;4(2):127-137.
Frenk E, Pathak MA, Szabó G, Fitzpatrick TB. Selective action of mercaptoethylamines on melanocytes in mammalian skin: experimental depigmentation. Arch Dermatol. 1968;97(4):465-477.
Kasraee B, Hügin A, Tran C, Sorg O, Saurat J-H. Methimazole is an inhibitor of melanin synthesis in cultured B16 melanocytes. J Invest Dermatol. 2004;122(5):1338.
Chan C-F, Lai S-T, Guo Y-C, Chen M-J. Inhibitory effects of novel synthetic methimazole derivatives on mushroom tyrosinase and melanogenesis. Bioorg Med Chem. 2014;22(9):2809-2815.
Moseley H, MacFadyen E, Ferguson M, Simpson N. Reduction of UV-induced erythema in normal subjects by applying methimazole. Photo-dermatology. 1989;6(1):32-36.
Malek J, Chedraoui A, Nikolic D, Barouti N, Ghosn S, Abbas O. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Dermatol Ther. 2013;26(1):69-72.
Atefi N, Behrangi E, Nasiripour S, et al. Blind randomized trial of efficacy and safety of 5% methimazole versus 2% hydroquinone in patients with melasma. J Skin Stem Cell. 2016;4:2.
Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: a systematic review. J Am Acad Dermatol. 2019;80(4):957-969.
Kasraee B, Ardekani GS, Parhizgar A, et al. Safety of topical methimazole for the treatment of melasma. Skin Pharmacol Physiol. 2008;21(6):300-305.
Gianetti E, Russo L, Orlandi F, et al. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest. 2015;38(9):977-985.